Earnings Call Summary | Imunon(IMNN.US) Q1 2024 Earnings Conference
Earnings Call Summary | Imunon(IMNN.US) Q1 2024 Earnings Conference
The following is a summary of the Imunon, Inc. (IMNN) Q1 2024 Earnings Call Transcript:
以下是Imunon, Inc.(IMNN)2024年第一季度财报电话会议记录摘要:
Financial Performance:
财务业绩:
Imunon reported a net loss for Q1 2024 of $4.9 million or $0.52 per share, a decrease from a net loss of $5.6 million or $0.68 per share for the same period last year.
Operating expenses were $5 million, marking a decrease of 12% from last year, with R&D expenses amounting to $3.3 million.
Cash and investment balance as of March 31, 2024, stood at $9.8 million.
The costs associated with PlaCCine DNA vaccine technology platform were $1.6 million for Q1 2024, which is higher compared to $1.4 million in Q1 2023.
Costs associated with developing in-house pilot manufacturing capabilities decreased to $300,000 in Q1 2024, from $600,000 in Q1 2023.
General and administrative expenditures reduced to $1.7 million in Q1 2024, primarily due to lowered non-cash compensation expense, employee-related costs, consulting and legal fees, as well as reduced premiums on their D&O insurance.
Imunon报告称,2024年第一季度的净亏损为490万美元,合每股亏损0.52美元,低于去年同期的净亏损560万美元或每股亏损0.68美元。
运营支出为500万美元,比去年下降了12%,研发费用为330万美元。
截至2024年3月31日,现金和投资余额为980万美元。
2024年第一季度与PlacCine DNA疫苗技术平台相关的成本为160万美元,高于2023年第一季度的140万美元。
与开发内部试点制造能力相关的成本从2023年第一季度的60万美元降至2024年第一季度的30万美元。
2024年第一季度的一般和管理支出减少至170万美元,这主要是由于非现金薪酬支出、员工相关成本、咨询和律师费的降低,以及其D&O保险的保费降低。
Business Progress:
业务进展:
Imunon is advancing its lead investigational immunotherapy for ovarian cancer and anticipates reporting Phase 2 top-line results by mid-2024. A second study, conducted by Breakthrough Cancer Foundation and MD Anderson Cancer Center with IMNN-001 is also planned.
The company received FDA approval for a Phase 1 protocol for a seasonal COVID-19 booster with enrollment underway.
Imunon has welcomed new CEO, Stacy Lindborg, a veteran in the industry with over 30 years of experience.
The focus for the future includes advancing TheraPlas and PlaCCine technology platforms, with potential applications in intraperitoneal cancers and various viral pathogens.
Imunon正在推进其主要的卵巢癌研究性免疫疗法,并预计到2024年中期报告2期的顶级结果。突破癌症基金会和医学博士安德森癌症中心还计划进行第二项针对 IMNN-001 的研究。
该公司获得美国食品药品管理局批准了季节性 COVID-19 加强剂的第 1 阶段协议,注册正在进行中。
Imunon迎来了新任首席执行官史黛西·林德博格,她是该行业的资深人士,拥有30多年的经验。
未来的重点包括推进TheraPLAS和PlacCine技术平台,其潜在应用于腹膜内癌症和各种病毒病原体。
More details: Imunon IR
更多详情: Imunon IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:欲了解更多详情,请访问投资者关系网站。本文仅供投资者参考,不构成任何投资建议。
译文内容由第三方软件翻译。